OakChart

Cue Biopharma Inc

CUEHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 9:50 AM ET

19.41+0.65 (3.44%)
2026-11-11 15:55 CET
Market cap
136.28 USD m
Revenue, TTM
37.65 USD m
Net income, TTM
-164.11 USD m
Free cash flow, TTM
-50.17 USD m
EPS diluted, TTM
-27.00
P/E
-
Compare

Price

CUE against its 20, 50 and 200-day averages
2050200earnings
20.0030.0040.001.8M3.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CUEclose 19.4120-day 19.0250-day 24.37200-day 21.5119.41

57.4% under 45.50 on 10 Jul 2026. Last 15 sessions, 33.3% high to low

Profile

CUE
52-week range, 36% of the way up
4.9745.50

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Employees29
IPOJan 02, 2018
Beta2.82
ATR, 14d2.38
Rel volume0.13
Short float14.80%
Insider own19.77%
Inst own23.36%

Snapshot

6 groups

Valuation

Index-
Market Cap140.97M
Enterprise Value132.39M
Income-164.11M
Sales37.65M
Book/sh0.44
Cash/sh2.39
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees29
IPOJan 02, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S3.74
P/B43.93
P/C8.11
P/FCF-
EV/EBITDA-
EV/Sales3.52
Quick Ratio1.25
Current Ratio1.25
Debt/Eq3.81
LT Debt/Eq3.11
Option/ShortNo / Yes

Earnings

EPS (ttm)-27.00
EPS next Y-7.44
EPS next Q-2.24
EPS this Y-197.74%
EPS next Y70.24%
EPS next 5Y7.19%
EPS past 3/5Y42.63% 29.04%
Sales past 3/5Y180.45% 54.16%
EPS Y/Y TTM-63.33%
Sales Y/Y TTM354.37%
EPS Q/Q-805.64%
Sales Q/Q166.66%
EarningsAug 14 AMC
EPS/Sales Surpr.-1328.40% 162.57%

Ownership

Insider Own19.77%
Insider Trans-5.70%
Inst Own23.36%
Inst Trans20.66%
ROA-459.60%
ROE-1603.48%
ROIC-1729.46%
Gross Margin99.31%
Oper. Margin-261.97%
Profit Margin-435.83%
SMA202.02%
SMA50-20.38%
SMA200-9.80%
Trades-

Technical

Shs Outstand7.26M
Shs Float5.83M
Short Float14.80%
Short Ratio3.32
Short Interest0.86M
52W High45.50 -57.35%
52W Low4.97 290.36%
Volatility12.95% 11.93%
ATR (14)2.38
RSI (14)45.71
Beta2.82
Rel Volume0.13
Avg Volume259.55K
Volume3,777

Performance

Perf Week-2.19%
Perf Month-0.84%
Perf Quarter-37.56%
Perf Half Y-34.15%
Perf YTD111.80%
Perf Year-5.30%
Perf 3Y-72.00%
Perf 5Y-95.71%
Perf 10Y-
Recom1.00
Target Price88.00
Prev Close18.76
Price19.41
Change %3.44%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 18, 2026InitiatedRB. Riley SecuritiesBuy$83+327.7%
Mar 13, 2024InitiatedJJefferiesBuy$6-69.1%
Jun 26, 2023ResumedOOppenheimerOutperform$10-48.5%
Nov 21, 2022InitiatedPPiper SandlerOverweight$7-63.9%
Jan 13, 2022InitiatedHH.C. WainwrightBuy$20+3.1%
Jan 03, 2022InitiatedCCraig HallumBuy$28+44.3%
Nov 24, 2020InitiatedBBerenbergBuy$30+54.6%
Apr 09, 2020InitiatedSStifelBuy$21+8.2%
Jan 28, 2020InitiatedBBTIG ResearchBuy$26+34.0%
Jan 22, 2020InitiatedJJMP SecuritiesMkt Outperform$22+13.4%

Peers

Mkt cap
TickerCompanyMkt cap
EVMNEvommune Inc304.13M
JSPRJasper Therapeutics Inc16.09M
CLDXCelldex Therapeutics Inc2.42B
UPBUpstream Bio Inc187.86M
NKTRNektar Therapeutics1.31B
SPRYARS Pharmaceuticals Inc394.18M
CABACabaletta Bio Inc308.48M
HOWLWerewolf Therapeutics Inc47.63M
REGNRegeneron Pharmaceuticals Inc93.52B
NVSNovartis AG ADR292.70B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ray SumitaChief Legal Compliance OfficerOct 12 '26Sale28.051,84451,724116,701Oct 14 09:39 PM
Meluzio Michael VincentVP, Prin. Accounting OfficerOct 12 '26Sale28.051,14432,08947,817Oct 14 09:38 PM
Lin Shao-LeeChief Executive OfficerOct 12 '26Sale27.5511,087305,490694,908Oct 14 09:37 PM
Shao-Lee LinOfficerOct 12 '26Proposed Sale27.5511,087305,490Oct 13 08:56 PM
Sumita RayOfficerOct 12 '26Proposed Sale28.051,84451,724Oct 13 08:53 PM
Ray SumitaChief Legal Compliance OfficerAug 13 '26Option Exercise0.0018,1960127,374Aug 17 06:22 PM
Ray SumitaChief Legal Compliance OfficerAug 13 '26Sale30.098,829265,628118,545Aug 17 06:22 PM
Meluzio Michael VincentVP, Prin. Accounting OfficerAug 13 '26Option Exercise0.0013,647054,589Aug 17 06:19 PM
Meluzio Michael VincentVP, Prin. Accounting OfficerAug 13 '26Sale30.095,628169,32448,961Aug 17 06:19 PM
Lin Shao-LeeChief Executive OfficerAug 12 '26Option Exercise0.00109,1790764,253Aug 14 08:46 PM
Lin Shao-LeeChief Executive OfficerAug 12 '26Sale27.1040,0001,083,989724,253Aug 14 08:46 PM
Lin Shao-LeeChief Executive OfficerAug 13 '26Sale28.6218,258522,573705,995Aug 14 08:46 PM
Shao-Lee LinOfficerAug 12 '26Proposed Sale27.0140,0001,080,400Aug 14 08:45 PM
Sumita RayOfficerAug 13 '26Proposed Sale30.148,829266,106Aug 13 09:50 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
AVTMAvantis Total Equity Markets ETFAUM: 758.92M

News

latest 14 of 206
  • An orexin drugs proof-of-concept in ADHD; Cues unwarranted share slide (BioPharma Dive) +9.30%
  • Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results (InvestorsHub) -23.70%
  • Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria (GlobeNewswire)
  • Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) +10.04% -19.18%
  • Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission (GlobeNewswire)
  • Loading…
  • Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development (GlobeNewswire) -15.93%
  • Cue Biopharma Announces $50.0 Million Private Placement (GlobeNewswire)
  • Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution (GlobeNewswire) +18.93% -5.97%
  • Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +6.82%
  • Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments (GlobeNewswire) -14.05% -9.16%
  • Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.15%
  • Cue Biopharma Announces $30 Million Private Placement (GlobeNewswire) +13.38% +106.38%
  • Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-24.140-1.690-24.1407.883.001
2026Q12026-05-14-1.080--1.0775.69--
2025Q42026-03-16--0.01021.94--
2025Q32025-11-12-2.100-2.799-2.2152.152.293
2025Q22025-08-12-2.700-3.900-2.6662.952.001
2025Q12025-05-12-5.100-4.599-4.9520.421.273
2024Q42025-03-31-3.900-2.580-3.8371.581.705
2024Q32024-11-14-5.100-5.475-5.0713.341.524
2024Q22024-08-19-6.000-8.400-6.0812.661.293
2024Q12024-05-09-7.500-8.460-7.4881.721.215
2023Q42024-04-08-8.400-9.000-8.5491.820.973
2023Q32023-11-09-7.200-9.750-7.1222.101.314
2023Q22023-08-09-8.700-9.150-8.8301.380.914
2023Q12023-05-09-8.700-8.325-8.8070.191.954
2022Q42023-03-21-11.100-8.850-11.1760.150.104
2022Q32022-11-14-9.300-11.301-9.2880.070.513

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-49.800-51.450-49.9493.463.28
2020FY-46.800-45.486-46.8323.153.83
2021FY-42.300-46.101-42.34714.947.57
2022FY-44.700-40.575-44.6101.251.20
2023FY-33.300-35.901-33.2645.493.63
2024FY-21.600-22.080-21.6639.299.41
2025FY-8.400-12.000-8.40027.476.50
2026FY--25.010--15.62
2027FY--7.443--8.65
2028FY--6.715--12.28
2029FY--7.940--9.68
2030FY--9.545--7.78

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-153001.030.002.10
2026Q3S2026-08-262001.551.002.10
2026Q3S2026-08-171002.102.102.10
2026Q3S2026-08-151002.102.102.10
2026Q3S2026-08-141002.102.102.10
2026Q3S2026-05-151002.102.102.10
2026Q3S2025-11-261002.502.502.50
2026Q3S2025-11-172012.402.302.50
2026Q3S2025-11-132003.022.503.54
2026Q3S2025-11-112003.022.503.54
2026Q3S2025-11-102003.022.503.54
2026Q3S2025-11-092003.022.503.54
2026Q3S2025-11-082003.022.503.54
2026Q3S2025-11-072003.022.503.54

Estimate history

EPS, annual-64.8-58.081-49.949-46.832-42.347-44.61-33.264-21.663-8.424-27.0019
Period201720182019202020212022202320242025TTM
EPS, quarterly-6.081-5.071-3.837-4.952-2.666-2.2150.43-1.077-24.14
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual01.1433.4583.15414.9411.2455.499.28727.46637.65
Period201720182019202020212022202320242025TTM
Sales, quarterly2.6583.3361.5760.4212.9542.14921.9425.6867.877
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6490.690.8851.0121.0731.4351.5742.0613.2215.229
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.6212.0072.0612.0612.5482.5933.2213.2555.229
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue37.6527.479.295.491.2514.943.153.461.14
Cost of Goods Sold Incl. D&A0.260.352.353.441.81-1.78---
Gross Profit37.3927.126.942.05-0.5616.72---
Selling, General and Administrative Excl. Other136.0453.6448.5354.0552.9460.4347.1434.8739.08
Research and Development76.9737.4335.9340.2837.7640.1932.5926.6027.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-98.64-26.52-41.59-51.99-53.50-43.71-45.04-36.77-38.70
Interest Expense0.140.360.801.250.710.000.000.000.00
Unusual Expense-24.500.000.000.00-0.280.000.00--
Net Income Before Taxes-163.61-26.10-40.67-50.73-53.01-43.67-44.58-36.29-38.16
Income Taxes0.500.500.000.000.000.490.210.410.82
Consolidated Net Income-164.11-26.60-40.67-50.73-53.01-44.16-44.78-36.70-38.98
Net Income From Continuing Operations-164.11-26.60-40.67-50.73-53.01-44.16-44.78-36.70-38.98
Net Income-164.11-26.60-40.67-50.73-53.01-44.16-44.78-36.70-38.98
EPS (Recurring)-28.59-8.42-21.66-33.26-44.77-42.35-46.83-49.95-58.08
EPS (Basic, Before Extraordinaries)-26.99-8.42-21.66-33.26-44.61-42.35-46.83-49.95-58.08
EPS (Diluted)-27.00-8.42-21.66-33.26-44.61-42.35-46.83-49.95-58.08
EBITDA-98.38-26.17-39.24-48.56-51.70-45.49-43.99-31.41-37.94
Non-Operating Income (Expense)-89.330.781.722.500.930.050.460.480.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense25.903.756.858.189.508.417.654.765.67
Price To Sales Ratio5.311.056.6122.0081.5923.68113.78101.1882.82
Gross Margin99.3198.7374.7037.41-45.04111.90---
Operating Margin-261.97-96.56-447.86-947.03-4,296.52-292.56-1,427.96-1,063.21-3,386.71
Net Margin-435.83-96.85-437.97-924.10-4,257.09-295.56-1,419.79-1,061.18-3,411.53
Shares Outstanding5.233.222.061.571.431.071.010.890.69
Market Capitalization136.28136.2867.38119.13100.85364.21379.70421.6797.28

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue7.885.6921.942.152.950.421.583.34
Cost of Goods Sold Incl. D&A0.040.080.070.080.100.88-0.88
Gross Profit7.845.6121.872.072.85-0.46-2.46
Selling, General and Administrative Excl. Other95.5410.9719.929.6111.4911.8411.2111.37
Research and Development48.986.8316.474.697.828.457.189.38
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-87.69-5.361.96-7.54-8.63-12.30-9.63-8.91
Interest Expense0.010.000.050.070.040.130.150.19
Unusual Expense-24.49-0.010.000.000.000.000.000.00
Net Income Before Taxes-153.07-5.182.08-7.45-8.48-12.26-9.50-8.66
Income Taxes0.000.000.500.000.000.000.000.00
Consolidated Net Income-153.07-5.181.58-7.45-8.48-12.26-9.50-8.66
Net Income From Continuing Operations-153.07-5.181.58-7.45-8.48-12.26-9.50-8.66
Net Income-153.07-5.181.58-7.45-8.48-12.26-9.50-8.66
EPS (Recurring)-26.84-1.080.43-2.22-2.67-4.95-3.84-5.07
EPS (Basic, Before Extraordinaries)-24.14-1.080.44-2.22-2.67-4.95-3.84-5.07
EPS (Diluted)-24.14-1.080.43-2.22-2.67-4.95-3.84-5.07
EBITDA-87.66-5.292.03-7.46-8.54-11.42-9.87-8.03
Non-Operating Income (Expense)-89.850.180.180.170.200.170.290.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense23.840.050.481.531.261.341.561.58
Price To Sales Ratio5.311.011.2310.217.868.478.714.07
Gross Margin99.5498.6599.6996.3296.61-109.26-73.65
Operating Margin-1,113.30-94.328.92-351.05-292.32-2,921.38-610.98-267.15
Net Margin-1,943.21-91.077.22-346.58-287.14-2,911.40-602.54-259.59
Shares Outstanding5.233.263.222.592.552.062.062.01
Market Capitalization136.2822.4529.5155.9052.1656.3267.3845.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments27.1422.4648.5176.2964.3784.8759.4139.2663.58
Short Term Receivables7.450.941.700.063.141.420.750.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.401.731.240.840.951.240.861.351.48
Total Current Assets36.9825.1451.4577.1968.4787.5361.0240.6165.07
Net Property, Plant & Equipment4.324.847.1210.7011.928.887.182.781.69
Total Investments and Advances0.150.150.150.150.150.150.150.150.00
Intangible Assets--------0.20
Deferred Tax Assets0.93--------
Other Assets0.762.062.813.242.862.973.251.820.00
Total Assets43.1532.1961.5391.2883.4099.5371.6145.3666.95
Short Term Debt Incl. Current Port. of LT Debt1.917.877.335.264.934.784.450.000.00
Accounts Payable3.952.823.502.732.592.070.882.041.33
Other Current Liabilities7.632.996.253.555.279.476.324.184.02
Total Current Liabilities13.4913.6917.0811.5512.7916.3211.666.225.35
Long Term Debt2.291.007.3614.055.122.371.350.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.93--------
Other Liabilities0.000.000.000.000.001.944.025.170.00
Total Liabilities16.7114.6924.4525.6017.9120.6217.0211.395.35
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity26.4317.5037.0965.6865.4978.9154.5833.9761.61
Total Shareholders Equity26.4317.5037.0965.6865.4978.9154.5833.9761.61
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity26.4317.5037.0965.6865.4978.9154.5833.9761.61
Total Liabilities & Stockholders Equity43.1532.1961.5391.2883.4099.5371.6145.3666.95
Book Value Per Share8.218.4923.5645.7861.0178.0061.6549.2494.98
Tangible Book Value Per Share8.218.4923.5645.7861.0178.0061.6549.2494.67
Full-Time Employees294153515750474628
Price to Book Ratio42.473.852.791.995.564.817.732.862.37
Return on Assets-70.62-86.80-66.40-60.69-48.28-52.34-62.75-69.41-55.83
Return on Equity-121.11-149.03-98.73-80.82-61.16-67.10-82.88-81.57-60.52
Return on Invested Capital-92.63-219.84-114.14-66.48-62.54-55.10-65.61-114.74-37.71
Quick Ratio2.741.843.016.685.355.365.246.5312.17
Current Ratio2.741.843.016.685.355.365.246.5312.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-164.11-26.60-40.67-50.73-53.01-44.16-44.78-36.70-38.98
Depreciation1.360.962.353.441.81-1.781.065.170.76
Other Funds (Non Cash)110.897.256.928.279.0411.4910.006.507.60
Funds from Operations-51.86-18.39-31.40-39.03-42.16-34.45-33.73-25.03-30.62
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.81-3.29-4.92-0.930.36-4.391.23-5.774.21
Cash from Operating Activities-50.05-21.69-36.33-39.96-41.81-38.84-32.49-30.80-26.41
Capital Expenditures-0.12-0.18-0.070.00-0.17-0.91-0.60-0.05-1.85
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.040.040.100.000.010.020.000.13-
Purchase or Sale of Investments0.210.210.0025.00-24.4510.005.053.37-18.50
Purchase of Investments-16.29-16.290.000.00-29.450.00-9.95-15.13-39.50
Sale Or Maturity of Investments16.5016.500.0025.005.0010.0015.0018.5021.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.130.070.0325.00-24.619.114.463.45-20.35
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock42.3230.7914.2413.8643.8019.2358.6150.794.18
Repurchase of Common Pref Stock0.000.000.000.00-0.20-0.75-0.27-0.090.00
Sale of Common Pref Stock42.3230.7914.2413.8644.0019.9858.8950.884.18
Proceedsfrom Stock Options40.6030.793.4113.3944.0017.3856.6849.004.17
Issuance or Reduction of Debt, Net-2.50-4.50-4.00-2.009.860.000.000.000.00
Change in Long Term Debt-2.50-4.50-4.00-2.009.860.000.000.000.00
Issuance of Long Term Debt0.000.000.000.009.860.000.000.000.00
Reduction of Long Term Debt-2.50-4.50-4.00-2.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities39.8226.2910.2411.8653.6619.2358.6150.794.18
Net Change in Cash-10.104.68-26.05-3.10-12.76-10.5030.5823.44-42.58
Free Cash Flow-50.17-21.86-36.40-39.96-41.98-39.75-33.09-30.84-28.27
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments17.3916.3827.1418.6727.4913.14
Short Term Receivables7.287.257.452.290.530.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.962.762.404.862.822.79
Total Current Assets26.6226.3936.9825.8230.8415.93
Net Property, Plant & Equipment3.213.614.324.915.574.11
Total Investments and Advances0.150.150.150.150.150.15
Deferred Tax Assets--0.93---
Other Assets0.720.720.760.762.242.06
Total Assets30.7130.8843.1531.6440.7122.25
Short Term Debt Incl. Current Port. of LT Debt1.631.561.913.494.536.95
Accounts Payable3.753.333.952.353.633.78
Other Current Liabilities15.842.507.639.6911.104.76
Total Current Liabilities21.227.3913.4915.5219.2515.50
Long Term Debt7.181.882.292.683.100.18
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.93---
Other Liabilities0.000.000.000.190.190.00
Total Liabilities28.409.2716.7118.4022.5515.67
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2.3121.6126.4313.2518.166.58
Total Shareholders Equity2.3121.6126.4313.2518.166.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2.3121.6126.4313.2518.166.58
Total Liabilities & Stockholders Equity30.7130.8843.1531.6440.7122.25
Book Value Per Share0.446.648.215.117.133.19
Tangible Book Value Per Share0.446.648.215.117.133.19
Full-Time Employees--29---
Price to Book Ratio42.471.041.124.222.878.56
Return on Assets-459.60-73.49-70.62-98.58-93.68-106.51
Return on Equity-1,603.48-138.52-121.11-195.19-195.55-221.66
Return on Invested Capital-1,613.10-22.055.52-46.75-39.89-181.42
Quick Ratio1.253.572.741.661.601.03
Current Ratio1.253.572.741.661.601.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-153.07-5.181.58-7.45-8.48-12.26
Depreciation0.040.570.680.08-0.680.88
Other Funds (Non Cash)107.400.401.131.962.781.38
Funds from Operations-45.63-4.213.39-5.41-6.38-10.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital16.63-6.73-4.47-3.622.971.82
Cash from Operating Activities-29.00-10.94-1.08-9.02-3.42-8.17
Capital Expenditures0.00-0.120.000.00-0.03-0.15
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.020.020.000.00
Purchase or Sale of Investments0.000.007.00-6.790.000.00
Purchase of Investments0.000.000.00-16.290.000.00
Sale Or Maturity of Investments0.000.007.009.500.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.127.02-6.77-0.03-0.15
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock30.020.3110.991.0018.800.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock30.020.3110.991.0018.800.00
Proceedsfrom Stock Options27.550.3112.740.0018.050.00
Issuance or Reduction of Debt, Net0.000.00-1.50-1.00-1.00-1.00
Change in Long Term Debt0.000.00-1.50-1.00-1.00-1.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-1.50-1.00-1.00-1.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities30.020.319.490.0017.80-1.00
Net Change in Cash1.01-10.7615.44-15.7914.36-9.32
Free Cash Flow-29.00-11.06-1.08-9.02-3.44-8.32

Revenue breakdown

Pharmaceutical Preparations2024: 9.29M 2025: 27.47M
United States2024: 9.29M 2025: 27.47M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.80%0.9M5.8M264.13K
2026-10-1513.59%0.8M5.8M271.66K
2026-09-3011.27%0.7M6.2M260.74K
2026-09-155.33%0.3M6.2M161.98K
2026-08-315.11%0.3M6.2M150.58K
2026-08-145.99%0.3M5.5M139.23K
2026-07-3110.83%0.3M3.2M477.45K
2026-07-159.44%0.3M3.3M544.70K
2026-06-307.89%0.3M3.8M753.81K
2026-06-157.27%0.3M3.8M745.38K
2026-05-297.41%0.3M3.8M749.68K
2026-05-157.05%0.3M3.6M735.71K
2026-04-308.92%0.3M3.2M370.56K
2026-04-157.77%0.3M3.2M290.90K
2026-03-312.75%0.1M3.2M53.23K
2026-03-132.34%0.1M3.2M44.16K
2026-02-271.97%0.1M3.0M39.66K
2026-02-132.18%0.1M3.0M39.12K
2026-01-302.39%0.1M3.0M39.87K
2026-01-152.04%0.1M3.0M29.31K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-08SCHEDULE 13G/ASEC
2026-09-218-KCurrent report2026-09-20SEC
2026-08-284/A2026-07-09SEC
2026-08-284/A2026-07-09SEC
2026-08-21SCHEDULE 13DSEC
2026-08-20EFFECTEffectiveness filing by commission orderSEC
2026-08-18CORRESPSEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-17UPLOADUpload SubmissionSEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13GSEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-08-033Initial statement of beneficial ownership of securities2026-07-30SEC
2026-08-038-KCurrent report2026-07-27SEC
2026-07-304/A2026-06-01SEC
2026-07-22DNotice of sales of securities on Form D (Regulation D)SEC
2026-07-154Statement of changes in beneficial ownership of securities2026-07-13SEC
2026-07-153Initial statement of beneficial ownership of securities2026-07-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000389.30K3
2026-090000
2026-08002.04M4
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1299.75K100
2025-110000

Institutional holders

Manager% owned
Bleichroeder LP8.83%
DRIEHAUS CAPITAL MANAGEMENT LLC6.96%
VANGUARD CAPITAL MANAGEMENT LLC3.85%
Ikarian Capital, LLC2.48%
Tetragon Partners GP Ltd2.23%
STEMPOINT CAPITAL LP1.60%
UBS Group AG1.53%
BlackRock, Inc.1.38%
ADAR1 Capital Management, LLC1.31%
Lion Point Capital, LP1.26%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.66%
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Extended Market Index Fund0.28%
iShares Micro-Cap ETF0.26%
Fidelity Total Market Index Fund0.10%
Fidelity Series Total Market Index Fund0.09%
Dimensional U.S. Small Cap ETF0.04%
VANGUARD BALANCED INDEX FUND0.04%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.02%
Fidelity Nasdaq Composite Index Fund0.02%

OakChart. CUE. Cached 15 minutes.